Telemedizin und Ethik "Sicht des Sozialethikers und Theologen

Die Digitalisierung und Vernetzung der Gesellschaft hat diese entscheidend verändert. Auch Denk- und Handlungsweisen in der Medizin werden durch die neuen Informationstechnologien in erheblichem Maße beeinflusst. Von welcher Art ist dieser Einfluss? Verändert sich das Arzt-Patienten-Verhältnis? Bekommen wir den "gläsernen Patienten"? Gibt es Auswirkungen auf die Berufsstände im Gesundheitswesen? Verändert diese Technologie die Sozialsysteme möglicherweise sogar grundsätzlich? Werden wir bald von intelligenten technischen Systemen beherrscht? Sollten wir (bedenkenlos) alles machen, was wir (technisch) könn(t)en? Wo sind die Grenzen, wo müssen wir bremsen? Müssen wir über eine neue Ethik nachdenken oder "ist alles schon mal da gewesen"? Diesen und ähnlichen Fragen gehen die Beiträge in dieser Buchpublikation nach. In einem ersten Teil werden zur Einführung und zur Anregung Zukunftsszenarien entwickelt, und zwar für die Gebiete Medizinische Bildgebung, Medizinische Robotik und Telemedizin. Der zweiteTeil reflektiert allgemein über ethische Aspekte der Informationstechnik und der Informationstechnik, zunächst ohne direkten Bezug zur Medizin. Dieser wird im dritten Teil hergestellt. Den Schwerpunkt bildet hier die Telemedizin, weil diese ein geeignetes Modell zur ethischen Diskussion über Technik und Medizin darstellt. Der vierte Teil enthält eine Diskussion zum Thema "Werden die neuen Entwicklungen von Informationstechnik in der Medizin zum Fluch oder zum Segen für die Gesellschaft?". Schließlich sind in einem fünften Teil die Ergebnisse und Erkenntnisse in Thesenform zusammenzufassen. Diese "Dresdner Thesen zu ethischen Aspekten der Telemedizin" sind nach der Veranstaltung in einem mehrmonatigen Prozess entstanden, an dem die Herausgeber und die Autoren beteiligt waren.

An analysis of the components of pain, function, and health-related quality of life in patients with failed back surgery syndrome treated with spinal cord stimulation or conventional medical management

Objectives: Failed back surgery syndrome (FBSS) patients experience pain, functional disability, and reduced health-related quality of life (HRQoL) despite anatomically successful surgery. Examining sub-dimensions of health outcomes measures provides insight into patient well-being. Materials and Methods: The international multicenter PROCESS trial collected detailed HRQoL (EuroQol-5D; Short-Form 36) and function (Oswestry Disability Index) information on 100 FBSS patients. Results: At baseline, patients reported moderate-to-severe leg and back pain adversely affecting all dimensions of function and HRQoL. Compared with conventional medical management alone, patients also receiving spinal cord stimulation (SCS) reported superior pain relief, function, and HRQoL at six months on overall and most sub-component scores. The majority of these improvements with SCS were sustained at 24 months. Nonetheless, 36-40% of patients experienced ongoing marked disability (standing, lifting) and HRQoL problems (pain/discomfort). Conclusions: Longer-term patient management and research must focus on these refractory FBSS patients with persisting poor function and HRQoL outcomes.

A bacterial artificial chromosome library for Biomphalaria glabrata, intermediate snail host of Schistosoma mansoni

To provide a novel resource for analysis of the genome of Biomphalaria glabrata, members of the international Biomphalaria glabrata Genome Initiative (biology.unm.edu/biomphalaria-genome.html), working with the Arizona Genomics Institute (AGI) and supported by the National Human Genome Research Institute (NHGRI), produced a high quality bacterial artificial chromosome (BAC) library. The BB02 strain B. glabrata, a field isolate (Belo Horizonte, Minas Gerais, Brasil) that is susceptible to several strains of Schistosoma mansoni, was selfed for two generations to reduce haplotype diversity in the offspring. High molecular weight DNA was isolated from ovotestes of 40 snails, partially digested with HindIII, and ligated into pAGIBAC1 vector. The resulting B. glabrata BAC library (BG_BBa) consists of 61824 clones (136.3 kb average insert size) and provides 9.05 × coverage of the 931 Mb genome. Probing with single/low copy number genes from B. glabrata and fingerprinting of selected BAC clones indicated that the BAC library sufficiently represents the gene complement. BAC end sequence data (514 reads, 299860 nt) indicated that the genome of B. glabrata contains ~ 63% AT, and disclosed several novel genes, transposable elements, and groups of high frequency sequence elements. This BG_BBa BAC library, available from AGI at cost to the research community, gains in relevance because BB02 strain B. glabrata is targeted whole genome sequencing by NHGRI.

Anti-leishmanial and structure-activity relationship of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives

A series of ring substituted 3-phenyl-1-(1,4-di-N-oxide quinoxalin-2-yl)-2-propen-1-one derivatives were synthesized and tested for in vitro leishmanicidal activity against amastigotes of Leishmania amazonensis in axenical cultures and murine infected macrophages. Structure-activity relationships demonstrated the importance of a radical methoxy at position R3', R4' and R5'. (2E)-3-(3,4,5-trimethoxy-phenyl)-1-(3,6,7-trimethyl-1,4-dioxy-quinoxalin-2-yl)-propenone was the most active. Cytotoxicity on macrophages revealed that this product was almost six times more active than toxic.

Assessing patient's belief on HIV testing before elective surgery: room for improvements in Switzerland !

Background: ln Switzerland no HIV test is performed without the patient's consent based on a Voluntary Counseling and Testing policy (VCT). We hypothesized that a substantial proportion of patients going through an elective surgery falsely believed that an HIV test was performed on a routine basis and that the lack of transmission of result was interpreted as being HIV negative. Method: All patients with elective orthopedic surgery during 2007 were contacted by phone in 2008. A structured questionnaire assessed their belief about routine preoperative blood analysis (diabetes, coagulation function, HIV test and cholesterol level) as well as result awareness and interpretation. Variables included age and gender. Analysis were conducted using the software JMP 6.0.3. Results: 1123 patients were included. 130 (12 %) were excluded (Le. unreachable, unable to communicate on the phone, not operated). 993 completed the survey (89 %). Median age was 51 (16-79). 50 % were female. 376 (38 %) patients thought they had an HIV test performed before surgery but none of them had one. 298 (79 %) interpreted the absence of result as a negative HIV test. A predictive factor to believe an HIV test had been done was an age below 50 years old (45 % vs 33 % for 16-49 years old and 50-79 years old respectively, p < 0.001). No difference was observed between genders. Conclusion: ln Switzerland, nearly 40 % of the patients falsely thought an HIV test had been performed on a routine basis before surgery and were erroneously reassured about their HIV status. These results should either improve the information given to the patient regarding preoperative exams, or motivate public health policy to consider HIV opt-out screening instead of VCT strategy.

A PRKAR1A Mutation Associated with Primary Pigmented Nodular Adrenocortical Disease in 12 Kindreds

CONTEXT: Primary pigmented nodular adrenocortical disease (PPNAD), a rare cause of corticotropin-independent Cushing syndrome, can be part of Carney complex (CNC), an autosomal dominant multiple neoplasia syndrome characterized by spotty skin pigmentation, cardiac myxomas, and endocrine tumors or be isolated (i). Germline PRKAR1A-inactivating mutations have been observed in both CNC and iPPNAD, but with no apparent genotype-phenotype correlation. OBJECTIVE:The objectives of the study were a detailed phenotyping for CNC manifestations in 12 kindreds bearing the same PRKAR1A mutation and a study of the consequences of the mutation and a potential founder effect. DESIGN: The study consisted of descriptive case reports. SETTING: The study was conducted at two referral centers. PATIENTS: The patients described in this study were referred for PRKAR1A gene mutation analysis because of a diagnosis of apparently iPPNAD. RESULTS: We describe a 6-bp polypyrimidine tract deletion [exon 7 IVS del (-7-->-2)] in 12 unrelated kindreds that were referred for Cushing syndrome due to PPNAD. Nine of the patients had no family history; in two, there was a family history of iPPNAD. Only one patient met the criteria for CNC. Relatives carrying the same mutation had no manifestations of CNC or PPNAD, suggesting a low penetrance of this PRKAR1A defect. A founder effect was excluded by extensive genotyping of chromosome 17 markers. CONCLUSIONS: In conclusion, a small intronic deletion of the PRKAR1A gene is a low-penetrance cause of mainly iPPNAD; it is the first PRKAR1A genetic defect to have an association with a specific phenotype.

Nanopartikel am Arbeitsplatz

Nanopartikel sind sehr kleine Partikel, die gezielt so hergestellt sind, dass ihr Durchmesser kleiner als etwa 100 nm ist. Sie werden in der Industrie eingesetzt, weil Materialien mit solch kleinen Dimensionen oft neue Eigenschaften aufweisen, die sie vom Ursprungsmaterial unterscheidet. Das Potenzial für mögliche Gesundheits- und Umwelteffekte von Nanomaterialien wird zurzeit intensiv diskutiert, denn die möglichen Effekte der neuen Eigenschaften auf Umwelt und Gesundheit sind erst unvollständig geklärt. Für die Abklärung der Risiken ist es wichtig, Informationen über die möglichen Expositionen und mögliche Freisetzungen in die Umwelt zu haben. Bisher wurden aber Daten über eingesetzte Stoffmengen und Materialarten selten systematisch erhoben. Wir haben in der Schweiz eine repräsentative Studie durchgeführt, um den Einsatz von Nanopartikeln im gesamten Industriesektor abschätzen zu können. Diese Studie ist unseres Wissens weltweit die erste solche Studie. Sie verwendete die Definition von Nanopartikeln, welche Nanofasern und Agglomerate von Nanopartikeln mit einschließt. Geschätzte 1.300 Arbeiter in 600 Firmen sind direkt an einer Nanopartikelanwendung beteiligt und könnten somit exponiert werden. Dies sind etwa 0,6% der Firmen und etwa 0,08% der Arbeiter des Schweizer Produktionssektors. Um nun zu bestimmen, ob solche Arbeiter mit Nanopartikel in Kontakt kommen oder nicht, stehen verschiedene Messmethoden zur Verfügung. Die aktuelle Technik erlaubt eine quantitative Messung der Anzahl der Partikel in der Luft, deren Masse oder auch Oberfläche. Diese Messgrößen allein geben zwar Hinweise auf die Präsenz von Nanopartikeln, die möglichen Gesundheitseffekte einer Exposition sind aber erst unvollständig abgeklärt und erlauben keine abschließende Risikoanalyse für den Arbeitsplatz. Mehrere Aktionspläne für die Entwicklung eines sicheren und nachhaltigen Umgangs mit Nanomaterialien wurden in den letzten Jahren gestartet (EU, Schweiz). Internationale und nationale Organisationen entwickelten Guidelines und Empfehlungen für industrielle Anwendungen (Internationale Organisation für Normung - ISO, Schweizerische Unfallversicherungsanstalt - SUVA, Bundesanstalt für Arbeitsschutz und Arbeitsmedizin - BAuA, zusammen mit dem Verband der Chemischen Industrie - VCI). Diese generellen Informationen müssen nun in die Industrie transferiert und an die spezifischen Bedürfnisse der betroffenen Unternehmen angepasst werden. Die aufgezeigte, relativ geringe Verbreitung von Nanopartikelanwendungen in der Industrie weist darauf hin, dass heute Schutzmaßnahmen noch proaktiv und kostengünstig entwickelt und eingeführt werden können. Aber sollte die vorhergesagte "Nano-Revolution" wirklich eintreten, ist die Zeit gekommen, jetzt aktiv zu werden. [Autoren]

In vitro and in vivo experimental models for drug screening and development for Chagas disease

Chagas disease, a neglected illness, affects nearly 12-14 million people in endemic areas of Latin America. Although the occurrence of acute cases sharply has declined due to Southern Cone Initiative efforts to control vector transmission, there still remain serious challenges, including the maintenance of sustainable public policies for Chagas disease control and the urgent need for better drugs to treat chagasic patients. Since the introduction of benznidazole and nifurtimox approximately 40 years ago, many natural and synthetic compounds have been assayed against Trypanosoma cruzi, yet only a few compounds have advanced to clinical trials. This reflects, at least in part, the lack of consensus regarding appropriate in vitro and in vivo screening protocols as well as the lack of biomarkers for treating parasitaemia. The development of more effective drugs requires (i) the identification and validation of parasite targets, (ii) compounds to be screened against the targets or the whole parasite and (iii) a panel of minimum standardised procedures to advance leading compounds to clinical trials. This third aim was the topic of the workshop entitled Experimental Models in Drug Screening and Development for Chagas Disease, held in Rio de Janeiro, Brazil, on the 25th and 26th of November 2008 by the Fiocruz Program for Research and Technological Development on Chagas Disease and Drugs for Neglected Diseases Initiative. During the meeting, the minimum steps, requirements and decision gates for the determination of the efficacy of novel drugs for T. cruzi control were evaluated by interdisciplinary experts and an in vitro and in vivo flowchart was designed to serve as a general and standardised protocol for screening potential drugs for the treatment of Chagas disease.

Lung function in idiopathic pulmonary fibrosis--extended analyses of the IFIGENIA trial.

BACKGROUND The randomized placebo-controlled IFIGENIA-trial demonstrated that therapy with high-dose N-acetylcysteine (NAC) given for one year, added to prednisone and azathioprine, significantly ameliorates (i.e. slows down) disease progression in terms of vital capacity (VC) (+9%) and diffusing capacity (DLco) (+24%) in idiopathic pulmonary fibrosis (IPF). To better understand the clinical implications of these findings we performed additional, explorative analyses of the IFGENIA data set. METHODS We analysed effects of NAC on VC, DLco, a composite physiologic index (CPI), and mortality in the 155 study-patients. RESULTS In trial completers the functional indices did not change significantly with NAC, whereas most indices deteriorated with placebo; in non-completers the majority of indices worsened but decline was generally less pronounced in most indices with NAC than with placebo. Most categorical analyses of VC, DLco and CPI also showed favourable changes with NAC. The effects of NAC on VC, DLco and CPI were significantly better if the baseline CPI was 50 points or lower. CONCLUSION This descriptive analysis confirms and extends the favourable effects of NAC on lung function in IPF and emphasizes the usefulness of VC, DLco, and the CPI for the evaluation of a therapeutic effect. Most importantly, less progressed disease as indicated by a CPI of 50 points or lower at baseline was more responsive to therapy in this study.

Improved prediction of coronary heart disease with markers of atherosclerosis and of inflammation in older adults?

Background: Several markers of atherosclerosis and of inflammation have been shown to predict coronary heart disease (CHD) individually. However, the utility of markers of atherosclerosis and of inflammation on prediction of CHD over traditional risk factors has not been well established, especially in the elderly. Methods: We studied 2202 men and women, aged 70-79, without baseline cardiovascular disease over 6-year follow-up to assess the risk of incident CHD associated with baseline noninvasive measures of atherosclerosis (ankle-arm index [AAI], aortic pulse wave velocity [aPWV]) and inflammatory markers (interleukin-6 [IL-6], C-reactive protein [CRP], tumor necrosis factor-a [TNF-a]). CHD events were studied as either nonfatal myocardial infarction or coronary death ("hard" events), and "hard" events plus hospitalization for angina, or the need for coronary-revascularization procedures (total CHD events). Results: During the 6-year follow-up, 283 participants had CHD events (including 136 "hard" events). IL-6, TNF-a and AAI independently predicted CHD events above Framingham Risk Score (FRS) with hazard ratios [HR] for the highest as compared with the lowest quartile for IL-6 of 1.95 (95%CI: 1.38-2.75, p for trend <0.001), TNF-a of 1.45 (95%CI: 1.04-2.02, p for trend 0.03), of 1.66 (95%CI: 1.19-2.31) for AAI 0.9, as compared to AAI 1.01-1.30. CRP and aPWV were not independently associated with CHD events. Results were similar for "hard" CHD events. Addition of IL-6 and AAI to traditional cardiovascular risk factors yielded the greatest improvement in the prediction of CHD; C-index for "hard"/total CHD events increased from 0.62/0.62 for traditional risk factors to 0.64/0.64 for IL-6 addition, 0.65/0.63 for AAI, and 0.66/0.64 for IL-6 combined with AAI. Being in the highest quartile of IL-6 combined with an AAI 0.90 or >1.40 yielded an HR of 2.51 (1.50-4.19) and 4.55 (1.65-12.50) above FRS, respectively. With use of CHD risk categories, risk prediction at 5 years was more accurate in models that included IL-6, AAI or both, with 8.0, 8.3 and 12.1% correctly reclassified, respectively. Conclusions: Among older adults, markers of atherosclerosis and of inflammation, particularly IL-6 and AAI, are independently associated with CHD. However, these markers only modestly improve cardiovascular risk prediction beyond traditional risk factors.